On Friday, Enliven Therapeutics Inc (NASDAQ: ELVN) opened higher 7.75% from the last session, before settling in for the closing price of $18.57. Price fluctuations for ELVN have ranged from $13.30 to $30.03 over the past 52 weeks.
A company in the Healthcare sector has jumped its sales by 19.02% annually for the last half of the decade. Company’s average yearly earnings per share was noted -2.00% at the time writing. With a float of $41.86 million, this company’s outstanding shares have now reached $59.23 million.
Enliven Therapeutics Inc (ELVN) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Enliven Therapeutics Inc is 29.34%, while institutional ownership is 76.03%. The most recent insider transaction that took place on Sep 23 ’25, was worth 30,045. In this transaction CHIEF SCIENTIFIC OFFICER of this company sold 1,500 shares at a rate of $20.03, taking the stock ownership to the 931,688 shares. Before that another transaction happened on Sep 23 ’25, when Company’s PRESIDENT AND CEO sold 2,800 for $20.03, making the entire transaction worth $56,084. This insider now owns 919,092 shares in total.
Enliven Therapeutics Inc (ELVN) Latest Financial update
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.48 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.5) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -2.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -15.89% during the next five years compared to 19.02% growth over the previous five years of trading.
Enliven Therapeutics Inc (NASDAQ: ELVN) Trading Performance Indicators
Check out the current performance indicators for Enliven Therapeutics Inc (ELVN). In the past quarter, the stock posted a quick ratio of 32.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.00, a number that is poised to hit -0.43 in the next quarter and is forecasted to reach -2.21 in one year’s time.
Technical Analysis of Enliven Therapeutics Inc (ELVN)
Let’s dig in a bit further. During the last 5-days, its volume was 0.43 million. That was better than the volume of 0.4 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 51.72%.
During the past 100 days, Enliven Therapeutics Inc’s (ELVN) raw stochastic average was set at 49.01%, which indicates a significant decrease from 78.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.23 in the past 14 days, which was lower than the 1.36 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.85, while its 200-day Moving Average is $20.43. However, in the short run, Enliven Therapeutics Inc’s stock first resistance to watch stands at $20.95. Second resistance stands at $21.88. The third major resistance level sits at $23.22. If the price goes on to break the first support level at $18.68, it is likely to go to the next support level at $17.34. The third support level lies at $16.41 if the price breaches the second support level.
Enliven Therapeutics Inc (NASDAQ: ELVN) Key Stats
There are currently 59,236K shares outstanding in the company with a market cap of 1.19 billion. Presently, the company’s annual sales total 0 K according to its annual income of -89,020 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -25,340 K.
